ClinicalTrials.gg

Program

inebilizumab

Also written as “Inebilizumab”, “MEDI-551” and “MEDI-551 30 MG-IV”.

Its studies are mostly in Neuromyelitis Optica · Immunoglobulin G4-Related Disease · Myasthenia Gravis · Hepatitis, Autoimmune · Lupus Erythematosus, Systemic, led by 4 companies.

Furthest: phase 4, since Nov 17, 202319 company-led studies, 11 open or runningNext primary completion: Apr 13, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen109 open or runningphase 4since Nov 17, 2023Nov 5, 2019Apr 13, 2027phase 2 · NCT05549258
AstraZeneca70 open or runningphase 3since Jul 16, 2014Jul 23, 2009none ahead
Hansoh Pharmaceutical Group11 open or runningphase 4since Dec 15, 2023Dec 15, 2023none ahead
Tanabe Pharma11 open or runningphase 3since Jan 6, 2022Jan 6, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jul 23, 2009.

  1. Oct 1, 2013Phase 1 study in Hematologic NeoplasmsAstraZeneca · NCT01957579 · 32 enrolled · Japan
  2. Jul 16, 2014Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT02200770 · 231 enrolled · United States, Australia, Bulgaria and more
  3. Nov 5, 2019Amgen's first study: phase 2 study in Highly Sensitized Patients on Waiting List for Kidney TransplantationNew to AmgenAmgen · NCT04174677 · United States
  4. Aug 10, 2020Phase 3 study in Myasthenia GravisAmgen · NCT04524273 · 238 enrolled · United States, Argentina, Belarus and more
  5. Sep 1, 2020Phase 3 study in Immunoglobulin G4-Related DiseaseAmgen · NCT04540497 · 135 enrolled · United States, Argentina, Australia and more
  6. Jan 6, 2022Tanabe Pharma's first study: phase 3 study in Scleroderma, SystemicNew to Tanabe PharmaTanabe Pharma · NCT05198557 · 80 enrolled · Japan
  7. Jul 22, 2022Phase 2 study in Neuromyelitis OpticaAmgen · NCT05549258 · 15 planned · United States, Argentina, Brazil and more
  8. Nov 17, 2023Phase 4 study in Neuromyelitis OpticaAmgen · NCT06180278 · 32 enrolled · United States, China, Czechia and more
  9. Dec 15, 2023Hansoh Pharmaceutical Group's first study: phase 4 study in Neuromyelitis OpticaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06212245 · 33 planned · China
  10. Aug 22, 2024Phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798 · 220 planned · United States, Australia, Belgium and more
  11. May 16, 2025Phase 2 study in Myasthenia GravisAmgen · NCT06987539 · 15 planned · United States, Argentina, Brazil and more
  12. Oct 28, 2025Phase 2 study in Immunoglobulin G4-Related DiseaseAmgen · NCT07222553 · 15 planned · United States, Brazil, China and more
  13. May 14, 2026Phase 3 study in Hepatitis, AutoimmuneAmgen · NCT07598825 · 180 planned · United States, Belgium, Canada and more
  14. Sep 25, 2026Phase 3 study in Glomerulonephritis, MembranousAmgen · NCT07851220 · 159 planned · United States

Ahead

  1. Apr 13, 2027Primary completion: phase 2 study in Neuromyelitis OpticaAmgen · NCT05549258
  2. Jun 26, 2028Primary completion: phase 4 study in Neuromyelitis OpticaAmgen · NCT06180278
  3. Aug 6, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicAmgen · NCT06570798
  4. Mar 13, 2030Primary completion: phase 2 study in Myasthenia GravisAmgen · NCT06987539

TargetBeta

CD19 →read by rule
“A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 ”NCIt, by rule
“B-lymphocyte antigen CD19 binding agent”ChEMBL 37, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
rapcabtagene autoleucelNovartisphase 28

Studies

All 19 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07851220Glomerulonephritis, Membranous · United States3RecruitingAmgenSep 27, 2031159
NCT07598825Hepatitis, Autoimmune · United States, Belgium, Canada and more3RecruitingAmgenJul 30, 2031180
NCT07222553Immunoglobulin G4-Related Disease · United States, Brazil, China and more2RecruitingAmgenJun 10, 203115
NCT06987539Myasthenia Gravis · United States, Argentina, Brazil and more2RecruitingAmgenMar 13, 203015
NCT06570798Lupus Erythematosus, Systemic · United States, Australia, Belgium and more2RecruitingAmgenAug 6, 2028220
NCT06212245Neuromyelitis Optica · China4Not yet recruitingHansoh Pharmaceutical GroupDec 25, 202433
NCT06180278Neuromyelitis Optica · United States, China, Czechia and more4Active, not recruitingAmgenJun 26, 202832
NCT05549258Neuromyelitis Optica · United States, Argentina, Brazil and more2RecruitingAmgenApr 13, 202715
NCT05198557Scleroderma, Systemic · Japan3Active, not recruitingTanabe PharmaJul 31, 202580
NCT04540497Immunoglobulin G4-Related Disease · United States, Argentina, Australia and more3Active, not recruitingAmgenApr 9, 2024135
NCT04524273Myasthenia Gravis · United States, Argentina, Belarus and more3Active, not recruitingAmgenMay 28, 2024238
NCT04174677Highly Sensitized Patients on Waiting List for Kidney Transplantation · United States2WithdrawnAmgenDec 20210
NCT02200770Neuromyelitis Optica · United States, Australia, Bulgaria and more3CompletedAstraZenecaOct 26, 2018231
NCT01957579Hematologic Neoplasms · Japan1CompletedAstraZenecaSep 15, 201532
NCT01585766Multiple Sclerosis · United States, Poland, Spain and more1CompletedAstraZenecaJan 2, 201556
NCT01453205Lymphoma, Large B-Cell, Diffuse · United States, Canada, Czechia and more2CompletedAstraZenecaJul 11, 2016187
NCT01466153Leukemia, Lymphocytic, Chronic, B-Cell · United States, Belgium, Canada and more2CompletedAstraZenecaJan 8, 2016183
NCT00983619Neoplasms · United States, Belgium, Canada and more2CompletedAstraZenecaMar 21, 2019136
NCT00946699Scleroderma, Diffuse · United States, Canada, United Kingdom1CompletedAstraZenecaMar 201250

How it is read

Names in the registry

  • “Inebilizumab”, 12 entries
  • “MEDI-551”, 7 entries
  • “inebilizumab”, 1 entry
  • “MEDI-551 30 MG-IV”, 1 entry
  • “MEDI-551 60 MG-SC”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.